Document Detail


Effect of dexamethasone therapy on the neonatal ductus arteriosus.
MedLine Citation:
PMID:  9568218     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patent ductus arteriosus (PDA) is believed to be a contributing factor in the etiopathogenesis of bronchopulmonary dysplasia (BPD). We studied the effects of early dexamethasone therapy on persistent ductal patency and the role of PDA in the etiopathogenesis of BPD during the course of a randomized double-blind trial of dexamethasone to prevent BPD. Infants, who weighed between 700 and 999 g, had severe RDS, and had been given surfactant, were randomized to receive a 12-day course of dexamethasone (n = 13) or placebo (n = 17) starting within the first 12 hours of postnatal life. The diagnosis of PDA was made clinically and was confirmed by cardiac ultrasound. The incidence of clinically significant ductus in infants who weighed less than 1000 g was 23% in the dexamethasone-treated group, as compared with 59% in infants who were given placebo. This difference was marginally significant, p = 0.05, odds ratio 0.21, 95% confidence interval 0.04-1.05. None of the infants in the dexamethasone group had recurrence of PDA after indomethacin therapy as compared with three infants in the placebo group. Dexamethasone significantly reduced the number of days infants required ventilator and supplemental oxygen as compared with infants who received placebo. Dexamethasone, as compared with placebo, also reduced the incidence of BPD, p = 0.025, odds ratio 0.08, 95% confidence interval 0.01-0.58. Dexamethasone may reduce the incidence of PDA in premature infants who weigh less than 1000 g at birth and thereby reduce the incidence of BPD.
Authors:
P Morales; A Rastogi; M L Bez; S M Akintorin; S Pyati; S M Andes; R S Pildes
Related Documents :
2244608 - Midfacial hypoplasia associated with long-term intubation for bronchopulmonary dysplasia.
3322008 - A patient with partial duplication 2q and partial deficiency 11q.
3588058 - Decreased phosphatidyl choline content in bronchoalveolar lavage fluids of children wit...
16779858 - Inhaled drugs for the prevention and treatment of bronchopulmonary dysplasia.
23871478 - Infantile botulism: a case report and review.
3436278 - Differentiation of healthy newborns and newborns-at-risk by spectral analysis of heart ...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Pediatric cardiology     Volume:  19     ISSN:  0172-0643     ISO Abbreviation:  Pediatr Cardiol     Publication Date:    1998 May-Jun
Date Detail:
Created Date:  1998-05-21     Completed Date:  1998-05-21     Revised Date:  2008-02-20    
Medline Journal Info:
Nlm Unique ID:  8003849     Medline TA:  Pediatr Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  225-9     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, Cook County Children's Hospital, University of Illinois, Chicago, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Inflammatory Agents / therapeutic use*
Blood Pressure / drug effects
Bronchopulmonary Dysplasia / etiology,  prevention & control*
Dexamethasone / therapeutic use*
Double-Blind Method
Ductus Arteriosus, Patent / complications,  drug therapy*
Gestational Age
Humans
Infant, Newborn
Infant, Very Low Birth Weight
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 50-02-2/Dexamethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Persistent eustachian valves in infants: course and management in symptomatic patients.
Next Document:  The natural course of isolated ventricular septal defect during adolescence.